NAS
AKBA icon

Nicolet Advisory Services’s Akebia Therapeutics AKBA Stock Holding History

Nicolet Advisory Services’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$28K Hold
20,000
– – ﹤0.01% 419
2025
Q3 		$59K Hold
20,000
– – ﹤0.01% 409
2025
Q2 		$74.4K Hold
20,000
– – 0.01% 402
2025
Q1 		$31K Hold
20,000
– – ﹤0.01% 378
2024
Q4 		$35K Hold
20,000
– – ﹤0.01% 378
2024
Q3 		$26.4K Hold
20,000
– – ﹤0.01% 369
2024
Q2 		$21.6K Buy
+20,000
New +$24.7K ﹤0.01% 354

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nicolet Advisory Services's AKBA Position: Q4 2025 in Review

Nicolet Advisory Services held its Akebia Therapeutics (AKBA) position steady in Q4 2025 at 20,000 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #419.

Nicolet Advisory Services first reported a position in AKBA in Q2 2024 and has held it in 7 quarters since. The position peaked at $74.4K in Q2 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • Nicolet Advisory Services held 20,000 shares of Akebia Therapeutics worth $28K as of Q4 2025.
  • Nicolet Advisory Services left its Akebia Therapeutics share count unchanged in Q4 2025.
  • Akebia Therapeutics made up ﹤0.01% of Nicolet Advisory Services's portfolio in Q4 2025, its #419 holding.
  • Nicolet Advisory Services first reported a position in Akebia Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Nicolet Advisory Services's Akebia Therapeutics position peaked at $74.4K in Q2 2025.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Nicolet Advisory Services's 13F filing for Q4 2025, filed 13 Feb 2026.